Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder due to the lack of dystrophin production. The disease is characterized by muscle wasting, with the most common causes of death being respiratory failure or heart failure. Recently, exon skipping using a phosphorodiamidate morpholino oligomer (PMO) is used as an FDA approved treatment for DMD. Peptide-conjugated PMOs (PPMOs) are used to increase exon skipping efficacy in the heart and are a promising therapy for DMD. Researchers have previously relied on high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC/MS) methods for detecting PPMO uptake, but an enzyme-linked immunosorbent assay (ELISA) has been shown to have greater sensitivity. Here, we present methodologies to determine the uptake efficiency of a PPMO into the heart and efficacy of exon 51 skipping by a PPMO injected retro-orbitally into a humanized DMD mouse model via ELISA and RT-PCR, respectively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McNally EM, Pytel P (2007) Muscle diseases: the muscular dystrophies. Annu Rev Pathol 2:87–109. https://doi.org/10.1146/annurev.pathol.2.010506.091936
Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32:671–688. https://doi.org/10.1016/j.ncl.2014.05.002
Lee JJA, Yokota T (2016) Translational research in muscular dystrophy. Springer, New York, NY 87–102. doi: https://doi.org/10.1007/978-4-431-55678-7
Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140. https://doi.org/10.1038/nrd3625
Aoki Y, Nakamura A, Yokota T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18:1995–2005. https://doi.org/10.1038/mt.2010.186
Yokota T, Lu QL, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann Neurol 65:667–676. https://doi.org/10.1002/ana.21627
Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102:198–203. https://doi.org/10.1073/pnas.0406700102
Wein N, Vulin A, Findlay A et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4:199–207
Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533–545. https://doi.org/10.2147/DDDT.S97635
Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for duchenne muscular dystrophy. J Pers Med 7:4. https://doi.org/10.3390/jpm7040013
Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations. Hum Mutat 36:395–402. https://doi.org/10.1002/humu.22758
Shimizu-motohashi Y, Miyatake S, Komaki H et al (2016) Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res 8:2471–2489
Wu B, Moulton HM, Iversen PL et al (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci 105:14814–14819. https://doi.org/10.1073/pnas.0805676105
Kudoh H, Ikeda H, Kakitani M et al (2005) A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system. Biochem Biophys Res Commun 328:507–516. https://doi.org/10.1016/j.bbrc.2004.12.191
Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in duchenne muscular dystrophy. Mol Ther 25:2561–2572. https://doi.org/10.1016/j.ymthe.2017.07.014
Burki U, Keane J, Blain A et al (2015) Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides. Nucleic Acid Ther 25:275–284. https://doi.org/10.1089/nat.2014.0528
Rio DC (2014) Reverse transcription-polymerase chain reaction. Cold Spring Harb Protoc 2014:1207–1216. https://doi.org/10.1101/pdb.prot080887
Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci 114:4213–4218. https://doi.org/10.1073/pnas.1613203114
Acknowledgments
This work is supported by the Muscular Dystrophy Canada, the Friends of Garrett Cumming Research Fund, the HM Toupin Neurological Science Research Fund, the Canadian Institutes of Health Research (CIHR), the Alberta Innovates: Health Solutions (AIHS), the Canada Foundation for Innovation (CFI), the Alberta Advanced Education and Technology, and the Women and Children’s Health Research Institute (WCHRI).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Melo, D., Maruyama, R., Yokota, T. (2018). Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA. In: Yokota, T., Maruyama, R. (eds) Exon Skipping and Inclusion Therapies. Methods in Molecular Biology, vol 1828. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8651-4_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8651-4_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8650-7
Online ISBN: 978-1-4939-8651-4
eBook Packages: Springer Protocols